Huimei Zhou
Overview
Explore the profile of Huimei Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu M, Zhou H, Yang J, Cao D, Yuan Z
Sci Rep
. 2025 Feb;
15(1):4716.
PMID: 39922892
Ovarian clear cell carcinoma (OCCC) is resistant to chemotherapy, with limited treatment options for advanced and recurrent disease. The prevalence of OCCC differs by region. Assessing the expression of programmed...
2.
Zhang P, Sun C, Lin S, Lu C, Wen Z, Ge Z, et al.
Clin Chim Acta
. 2025 Jan;
569:120150.
PMID: 39889920
Background: Prostate cancer (PC) is the second most common malignant tumor in males and a leading cause of cancer-related morbidity and mortality among men. Early detection is essential for improving...
3.
Yuan Z, Zhou H, Cao D, Yang J, Liu Q
J Gynecol Oncol
. 2024 Oct;
PMID: 39453393
Objective: The study aimed to establish humanized patient-derived xenograft (PDX) mouse models of ovarian clear cell carcinoma (OCCC) and evaluate their therapeutic responses. Methods: PDX models and their humanized counterparts...
4.
Liu Q, Zhou H, Yu M, Cao D, Yang J
Trials
. 2024 Sep;
25(1):578.
PMID: 39223633
Background: Around 4% of women receive an endometrial cancer diagnosis before turning 40, mainly those without prior childbirth experience and a strong desire to preserve their ability to conceive. Consequently,...
5.
Zhou H, Liu Q, Zhang D, Li Q, Cao D, Cheng N, et al.
Int J Gynecol Cancer
. 2024 Jul;
34(11):1761-1767.
PMID: 39074931
Objective: Non-platinum chemotherapy is used in platinum resistant/refractory ovarian cancer patients but offers limited efficacy, especially in those who develop platinum resistance after ≤2 lines of platinum based chemotherapy. This...
6.
Zhou H, Li T, Zhu E, Wang S, Zhang Q, Li X, et al.
Int J Biol Macromol
. 2024 Jul;
275(Pt 1):133454.
PMID: 38964692
In the realization of the goal of circular economy, cellulose as one of sustainable biomass resources, have attracted much attention because of their abundant sources, biodegradability and renewability. However, the...
7.
He C, Zhou H, Chen L, Liu Z
Mol Neurobiol
. 2024 Jun;
62(1):846-860.
PMID: 38922486
Evidence suggests that long non-coding RNAs (lncRNAs) play a significant role in autism. Herein, we explored the functional role and possible molecular mechanisms of NEAT1 in valproic acid (VPA)-induced autism...
8.
Xu C, Wei Z, Dong X, Xing J, Meng X, Qiu Y, et al.
Biochem Pharmacol
. 2024 Jun;
226:116391.
PMID: 38914317
Inhibition of excessive osteoclastic activity is an efficient therapeutic strategy for many bone diseases induced by increased bone resorption, such as osteoporosis. BMS-582949, a clinical p38α inhibitor, is a promising...
9.
Chen S, Lu C, Lin S, Sun C, Wen Z, Ge Z, et al.
Front Genet
. 2024 May;
15:1371441.
PMID: 38818039
Prostate cancer (PCa) is one of the most prevalent malignancies affecting the male life cycle. The incidence and mortality of prostate cancer are also increasing every year. Detection of MicroRNA...
10.
Lu C, Lin S, Wen Z, Sun C, Ge Z, Chen W, et al.
Biomarkers
. 2024 May;
29(5):276-284.
PMID: 38767408
Background: Bladder cancer (BC) is one of the ten most common cancers worldwide with late detection and early age of diagnosis. There is abundant evidence that early detection and timely...